From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
Type of response
N (%)
Complete response
0
Partial response
14 (25%)
Stable disease
28 (51%)
Progressive disease
10 (18%)
Non-evaluable
3 (5%)